Drugmakers in China take aim at pharma’s lucrative cancer fighters
Checkpoint inhibitors have become blockbuster drugs in recent years, but now face new rivals developed in China.
BY BLOOMBERG NEWS
A coming wave of Chinese cancer drugs could provide patients with cheaper alternatives to some celebrated and costly therapies, but gaining traction will mean going up against some of the global pharmaceutical industry’s most lucrative and well-protected franchises.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
